Response to pegylated interferon in a COVID‐19–positive elderly woman with primary myelofibrosis treated with ruxolitinib

Response to pegylated interferon in a COVID‐19–positive elderly woman with primary myelofibrosis treated with ruxolitinib

Abstract An 83‐year‐old female had asymptomatic SARS‐CoV‐2 infection while taking ruxolitinib. She remained RT‐PCR positive for viral RNA for >120 days, and Pegylated interferon for 4 weeks led to viral RNA clearance. The observations support combination therapy of ruxolitinib + interferon for CO...

Full description

Bibliographic Details
Main Authors: Arthur E. Frankel, Renuka Reddy, Kayla R. DeSuza, Khaled Deeb, Aaron F. Carlin, Davey Smith, Yushuang Xie, Eknath Naik, Richard T. Silver, Hans C. Hasselbalch
Format: Article
Language:English
Published: Wiley 2021-04-01
Series:Clinical Case Reports
Subjects:
COVID‐19
interferon
ruxolitinib
Online Access:https://doi.org/10.1002/ccr3.3997
Description
Summary:Abstract An 83‐year‐old female had asymptomatic SARS‐CoV‐2 infection while taking ruxolitinib. She remained RT‐PCR positive for viral RNA for >120 days, and Pegylated interferon for 4 weeks led to viral RNA clearance. The observations support combination therapy of ruxolitinib + interferon for COVID‐19.
ISSN:2050-0904

Similar Items